SEC Info - Bristol-Myers Squibb Co.

SEC Info℠

Home

Help

Please Sign In

Bristol-Myers Squibb Co.
NJ
SEC # 14272

4 Related Registrants:

Click to view...

Registrant

About

Filings

Files

Relationships

Names

Topics

Web

*As Of*	*Filing*	*Page*	*Title*	*Docs.*

3/28/24	DEF 14A	1	A-1	2
2/16/24	424B5	1	About This Prospectus	4
		1	About This Prospectus Supplement	4
2/13/24	10-K	1	Acquisitions, Divestitures and Licensing Arrangements	1
3/28/24	DEF 14A	1	Active Board Oversight of Our Governance	2
		1	Advance Notice Procedures	2
		1	Advisory Vote to Approve the Compensation of our Named Executive Officers	2
2/13/24	10-K	1	Alliances	1
6/8/23	11-K	1	And 202	3
3/28/24	DEF 14A	1	Annual Evaluation Process	2
		1	Annual Incentive Plan Program Outcomes	2
		1	Annual Meeting of Shareholders	2
		1	Approval of an Amendment to our Amended and Restated Certificate of Incorporation	2
6/8/23	11-K	1	As of December 31, 202	3
3/28/24	DEF 14A	1	Audit and Non-Audit Fees	2
		1	Audit Committee Report	2
		1	Availability of Corporate Governance Documents	2
		1	Board Leadership Structure	2
		1	Board's Role in Strategic Planning and Risk Oversight	2
2/16/24	424B5	1	Book-Entry Issuance	4
3/28/24	DEF 14A	1	Bristol Myers Squibb	2
2/13/24	10-K	1	Bristol Myers Squibb Website	1
		1	Business	1
3/28/24	DEF 14A	1	Business Overview	2
2/16/24	424B5	1	Capitalization	4
3/28/24	DEF 14A	1	Categorical Standards of Independence	2
2/13/24	10-K	1	Certain Relationships and Related Transactions	1
		1	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1
3/28/24	DEF 14A	1	Codes of Conduct	2
		1	Committees of Our Board	2
		1	Common Stock Ownership by Directors and Executive Officers	2
		1	Compensation and Management Development Committee Report	2
		1	Compensation Committee Interlocks and Insider Participation	2
		1	Compensation Discussion and Analysis	2
		1	Compensation of Directors	2
2/13/24	10-K	1	Competition	1
4/25/24	10-Q	1	Consolidated Balance Sheets	5
		1	Consolidated Statements of Cash Flows	5
		1	Consolidated Statements of Earnings and Comprehensive (Loss)/Income	1
2/13/24	10-K	1	Consolidated Statements of Earnings and Comprehensive Income	4
4/25/24	10-Q	1	Controls and Procedures	5
3/28/24	DEF 14A	1	Criteria for Board Membership	2
2/13/24	10-K	1	Cybersecurity	1
2/16/24	424B5	1	Description of Capital Stock	4
		1	Description of Notes	4
		1	Description of the Company	4
		1	Description of the Debt Securities	4
		1	Description of the Depositary Shares	4
		1	Description of the Warrants	4
3/28/24	DEF 14A	1	Director Independence	2
		1	Director Succession Planning and Identification of Board Candidates	2
2/13/24	10-K	1	Directors, Executive Officers and Corporate Governance	1
		1	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	1
3/28/24	DEF 14A	1	Disclosure Regarding Political Activities	2
		1	Election of the Board of Directors	2
6/8/23	11-K	1	Ended December 31	1
2/13/24	10-K	1	Environmental Regulation	1
3/28/24	DEF 14A	1	Environmental, Social, Governance & Sustainability	2
		1	Equity Compensation Plan Information	2
2/13/24	10-K	1	Executive Compensation	1
3/28/24	DEF 14A	1	Executive Compensation Program Overview	2
		1	Exhibit A	2
2/13/24	10-K	1	Exhibit Index	1
4/25/24	10-Q	1	Exhibits	4
2/13/24	10-K	1	Exhibits and Financial Statement Schedule	1
		1	Exhibits Required to be filed by Item 601 of Regulation S-K	1
2/16/24	424B5	1	Experts	4
4/25/24	10-Q	1	Financial Statements	4
2/13/24	10-K	1	Financial Statements and Supplementary Data	1
6/8/23	11-K	1	For the Year	1
6/8/23	11-K	1	For the Year Ended December 31, 202	2
2/13/24	10-K	1	Foreign Operations	1
		1	Form 10-K Summary	1
6/8/23	11-K	1	Form 5500, Schedule H, Part IV, Line (4i) -- Schedule of Assets (Held at End of Year) as of December 31, 2	1
6/8/23	11-K	1	Form 5500, Schedule H, Part IV, Line (4i) -- Schedule of Assets (Held at End of Year) as of December 31, 20	2
2/16/24	424B5	1	Forward-Looking Statements	4
3/28/24	DEF 14A	1	Frequently Asked Questions	2
2/13/24	10-K	1	Government Regulation	1
3/28/24	DEF 14A	1	Grants of Plan-Based Awards	2
		1	Human Capital Management	2
2/13/24	10-K	1	Human Capital Management and Resources	1
3/28/24	DEF 14A	1	Inclusion & Diversity Aspirational Goals and Health Equity Commitments	2
2/16/24	424B5	1	Industry and Market Data	4
2/13/24	10-K	1	Information about our Executive Officers	1
		1	Item 1	1
		1	Item 10	1
		1	Item 11	1
		1	Item 12	1
		1	Item 13	1
		1	Item 14	1
		1	Item 15	1
		1	Item 16	1
		1	Item 1A	1
		1	Item 1B	1
		1	Item 1C	1
		1	Item 2	1
		1	Item 3	1
		1	Item 4	1
		1	Item 5	1
		1	Item 6	1
		1	Item 7	1
		1	Item 7A	1
		1	Item 8	1
		1	Item 9	1
		1	Item 9A	1
		1	Item 9B	1
		1	Item 9C	1
2/16/24	424B5	1	Legal Matters	4
4/25/24	10-Q	1	Legal Proceedings	5
3/28/24	DEF 14A	1	Majority Vote Standard and Director Resignation Policy	2
4/25/24	10-Q	1	Management's Discussion and Analysis of Financial Condition and Results of Operations	5
2/13/24	10-K	1	Manufacturing and Quality Assurance	1
		1	Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	1
		1	Marketing, Distribution and Customers	1
2/16/24	424B5	1	Material United States Federal Income Tax Considerations	4
3/28/24	DEF 14A	1	Meetings of Our Board & Director Engagement	2
		1	Message from Gerald Storch, Chair of the Compensation and Management Development Committee	2
2/13/24	10-K	1	Mine Safety Disclosures	1
3/28/24	DEF 14A	1	Named Executive Officers	2
		1	Non-Qualified Deferred Compensation Plan	2
4/25/24	10-Q	1	Notes to Consolidated Financial Statements	5
6/8/23	11-K	1	Notes to Financial Statements	3
2/13/24	10-K	1	Notes to the Financial Statements	1
3/28/24	DEF 14A	1	Option Exercises and Stock Vesting	2
4/25/24	10-Q	1	Other Information	4
3/28/24	DEF 14A	1	Outstanding Equity Awards at Fiscal Year-End	2
2/13/24	10-K	1	Part I	1
		1	Part Ia	1
		1	Part Ii	1
		1	Part Iii	1
		1	Part Iv	1
3/28/24	DEF 14A	1	Pay Ratio	2
		1	Pay Versus Performance	2
2/16/24	424B5	1	Plan of Distribution	4
3/28/24	DEF 14A	1	Policy on Hedging and Pledging	2
		1	Post-Termination Benefits	2
		1	Pre-Approval Policy for Services Provided by our Independent Registered Public Accounting Firm	2
		1	Present Value of Accumulated Pension Benefits	2
2/13/24	10-K	1	Pricing, Price Constraints and Market Access	1
		1	Principal Accountant Fees and Services	1
3/28/24	DEF 14A	1	Principal Holders of Voting Securities	2
		1	Proactive Shareholder Engagement	2
2/13/24	10-K	1	Products, Intellectual Property and Product Exclusivity	1
		1	Properties	1
4/25/24	10-Q	1	Quantitative and Qualitative Disclosure About Market Risk	4
2/13/24	10-K	1	Quantitative and Qualitative Disclosures About Market Risk	1
3/28/24	DEF 14A	1	Ratification of the Appointment of Independent Registered Public Accounting Firm	2
		1	Related Party Transactions	2
2/13/24	10-K	1	Report of Independent Registered Public Accounting Firm	4
		1	Research and Development	1
		1	Reserved	1
3/28/24	DEF 14A	1	Responsible Drug Pricing Strategy & Transparency	2
		1	Responsiveness to Shareholder Feedback	2
		1	Risk Assessment of Compensation Policies and Practices	2
4/25/24	10-Q	1	Risk Factors	9
2/16/24	424B5	1	S- 1	4
2/13/24	424B2	1	S- 11	1
11/1/23	424B5	1	S- 5	2
2/13/24	424B2	1	S- 6	1
2/16/24	424B5	1	S- 7	3
11/1/23	424B5	1	S- 8	2
2/13/24	424B2	1	S- 9	3
2/16/24	424B5	1	S- ii	4
		1	S- iii	4
		1	S- v	4
2/13/24	424B2	1	S-10	1
2/16/24	424B5	1	S-14	1
		1	S-15	1
		1	S-16	1
11/1/23	424B5	1	S-17	2
2/13/24	424B2	1	S-19	1
11/1/23	424B5	1	S-21	2
2/13/24	424B2	1	S-23	1
11/1/23	424B5	1	S-26	2
2/13/24	424B2	1	S-28	1
2/16/24	424B5	1	S-29	1
11/1/23	424B5	1	S-32	2
2/16/24	424B5	1	S-33	3
2/13/24	424B2	1	S-34	3
		1	S-35	1
		1	S-36	1
2/16/24	424B5	1	S-39	1
		1	S-46	1
		1	S-47	1
		1	S-48	1
6/8/23	11-K	1	Schedule of Assets (Held at End of Year) as of December 31, 2	1
6/8/23	11-K	1	Schedule of Assets (Held at End of Year) as of December 31, 20	2
2/13/24	10-K	1	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	1
3/18/24	PRE 14A	1	Shareholder Proposal on Director Election Resignation Bylaw	1
3/28/24	DEF 14A	1	Shareholder Proposal on Executives to Retain Significant Stock	2
		1	Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director	2
4/25/24	10-Q	1	Signatures	5
2/13/24	10-K	1	Sources and Availability of Raw Materials	1
6/8/23	11-K	1	Statement of Changes in Net Assets Available For Benefits -- For the Year	1
6/8/23	11-K	1	Statement of Changes in Net Assets Available For Benefits -- For the Year Ended December 31, 202	2
		1	Statements of Net Assets Available For Benefits -- As of December 31, 202	3
3/28/24	DEF 14A	1	Story, The	2
2/16/24	424B5	1	Summary	4
3/28/24	DEF 14A	1	Summary Compensation Table	2
4/25/24	10-Q	1	Summary of Abbreviated Terms	5
3/28/24	DEF 14A	1	Table of Contents	6
		1	Tax Implications of Executive Compensation Program	2
		1	Termination of Employment Obligations (Excluding Vested Benefits)	2
		1	The Story	2
		1	To Provide for Limited Officer Exculpation	2
2/16/24	424B5	1	Underwriting	4
4/25/24	10-Q	1	Unregistered Sales of Equity Securities and Use of Proceeds	4
2/13/24	10-K	1	Unresolved Staff Comments	1
2/16/24	424B5	1	Use of Proceeds	4
		1	Validity of the Notes	4
		1	Where You Can Find More Information; Documents Incorporated by Reference	4
3/28/24	DEF 14A	1	Who We Are	2
		1	Written Communication	2
6/8/23	11-K	1	022	1
3/18/24	PRE 14A	1	100	1
3/28/24	DEF 14A	1	102	1
		1	104	1
		1	104-105	1
		1	105	1
		1	106	1
		1	107	1
		1	11-13	2
2/13/24	10-K	1	120	1
		1	123	1
		1	125	1
		1	126	1
		1	127	1
		1	129	1
		1	130	1
3/18/24	PRE 14A	1	14-24	1
3/28/24	DEF 14A	1	14-26	1
6/8/23	11-K	1	202	1
3/28/24	DEF 14A	1	2023 Annual Incentive Award Payments	2
		1	2023 Business Results	2
		1	2023 Compensation Program -- Named Executive Officers	2
		1	2023 Individual Executive Performance Assessment	2
		1	2023 Long-Term Incentive Program Grants	2
		1	2023 Market Share Unit Awards	2
		1	2023 Named Executive Officers	2
		1	2023 Performance Share Unit Awards	2
		1	2024 Director Nominees	2
		1	2025 Shareholder Proposals	2
3/18/24	PRE 14A	1	25-28	1
3/28/24	DEF 14A	1	27-30	1
3/18/24	PRE 14A	1	29-30	1
3/28/24	DEF 14A	1	31-32	1
3/18/24	PRE 14A	1	31-33	1
3/28/24	DEF 14A	1	33-35	1
3/18/24	PRE 14A	1	34-85	1
3/28/24	DEF 14A	1	36-92	1
		1	6-103	1
3/18/24	PRE 14A	1	6-96	1
		1	97-98	1

↑Top

Bristol-Myers Squibb Co. NJ SEC # 14272

497 Topics within the Past Year Past Two Years Past Three Years Past Four Years Past Five Years Entire Database

Bristol-Myers Squibb Co.
NJ
SEC # 14272

497 Topics
within the